ANAVEX2-73

ANAVEX2-73 (also known as blarcamesine) is an experimental drug developed by Anavex Life Sciences for the treatment of Alzheimer's disease, Parkinson's disease, and other central nervous system (CNS) diseases. It is a sigma-1 receptor agonist and muscarinic receptor antagonist that is believed to have neuroprotective and anti-inflammatory effects.

Mechanism of Action

ANAVEX2-73 works by targeting the sigma-1 receptor, a chaperone protein at the endoplasmic reticulum (ER) which modulates the ER stress response and has been implicated in the pathogenesis of neurodegenerative diseases. By activating the sigma-1 receptor, ANAVEX2-73 is thought to restore the function of cells damaged by stress, inflammation, and mutations.

In addition to its action on the sigma-1 receptor, ANAVEX2-73 also acts as an antagonist at the muscarinic acetylcholine receptor M1, which is involved in memory and learning and is often dysregulated in Alzheimer's disease.

Clinical Trials

ANAVEX2-73 has undergone several clinical trials to evaluate its safety and efficacy in treating Alzheimer's disease and other CNS diseases. The results of these trials have shown promise, but further research is needed to fully understand the drug's potential benefits and risks.

Potential Applications

While the primary focus of ANAVEX2-73 research has been on Alzheimer's disease, the drug's mechanism of action suggests it could have potential applications in other neurodegenerative diseases as well, including Parkinson's disease, Huntington's disease, and ALS.

See Also

• Sigma-1 receptor
• Muscarinic acetylcholine receptor M1
• Anavex Life Sciences
• Alzheimer's disease
• Parkinson's disease